Quantinno Capital Management LP Has $5.30 Million Stock Holdings in Qiagen N.V. $QGEN

Quantinno Capital Management LP reduced its position in Qiagen N.V. (NYSE:QGEN) by 40.6% in the 1st quarter, according to its most recent filing with the SEC. The firm owned 132,392 shares of the company’s stock after selling 90,444 shares during the period. Quantinno Capital Management LP owned 0.06% of Qiagen worth $5,301,000 at the end of the most recent reporting period.

Several other large investors have also made changes to their positions in the company. Massachusetts Financial Services Co. MA boosted its stake in Qiagen by 1.1% in the fourth quarter. Massachusetts Financial Services Co. MA now owns 24,205,881 shares of the company’s stock valued at $1,088,538,000 after acquiring an additional 264,921 shares during the last quarter. Vanguard Group Inc. boosted its position in shares of Qiagen by 1.3% in the 4th quarter. Vanguard Group Inc. now owns 9,542,944 shares of the company’s stock worth $433,871,000 after purchasing an additional 118,135 shares during the last quarter. Price T Rowe Associates Inc. MD grew its stake in shares of Qiagen by 12.1% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 8,429,424 shares of the company’s stock worth $379,072,000 after purchasing an additional 906,589 shares during the period. Deutsche Bank AG increased its holdings in Qiagen by 9.7% in the fourth quarter. Deutsche Bank AG now owns 7,907,801 shares of the company’s stock valued at $355,614,000 after purchasing an additional 697,342 shares during the last quarter. Finally, Amundi lifted its stake in Qiagen by 4.4% in the third quarter. Amundi now owns 4,290,273 shares of the company’s stock valued at $201,471,000 after buying an additional 181,509 shares during the period. Institutional investors and hedge funds own 70.00% of the company’s stock.

Qiagen Stock Performance

Shares of QGEN opened at $41.71 on Friday. The firm has a market cap of $8.59 billion, a P/E ratio of 21.37, a PEG ratio of 4.19 and a beta of 0.63. Qiagen N.V. has a twelve month low of $32.53 and a twelve month high of $57.81. The company has a debt-to-equity ratio of 0.49, a quick ratio of 2.57 and a current ratio of 3.21. The firm’s 50 day moving average price is $39.32 and its two-hundred day moving average price is $41.69.

Qiagen (NYSE:QGEN) last issued its quarterly earnings data on Wednesday, August 5th. The company reported $0.62 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.60 by $0.02. The company had revenue of $535.00 million during the quarter, compared to the consensus estimate of $527.50 million. Qiagen had a net margin of 19.49% and a return on equity of 14.24%. The firm’s revenue was up .2% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $0.60 earnings per share. Qiagen has set its FY 2026 guidance at 2.430- EPS. On average, analysts forecast that Qiagen N.V. will post 2.43 EPS for the current fiscal year.

Qiagen Increases Dividend

The company also recently declared an annual dividend, which was paid on Tuesday, July 14th. Shareholders of record on Tuesday, July 7th were paid a $0.35 dividend. The ex-dividend date of this dividend was Tuesday, July 7th. This represents a dividend yield of 90.0%. This is a positive change from Qiagen’s previous annual dividend of $0.26. Qiagen’s dividend payout ratio (DPR) is 18.32%.

Analysts Set New Price Targets

A number of analysts have recently commented on the company. Morgan Stanley raised Qiagen from an “overweight” rating to an “overweight” rating and upped their price target for the company from $40.00 to $42.00 in a research note on Tuesday, June 23rd. Jefferies Financial Group restated a “buy” rating and set a $48.00 price objective on shares of Qiagen in a report on Thursday. Berenberg Bank set a $45.50 target price on shares of Qiagen and gave the stock a “hold” rating in a report on Tuesday, July 14th. TD Cowen reissued a “hold” rating on shares of Qiagen in a report on Wednesday, July 15th. Finally, Citigroup reaffirmed a “hold” rating on shares of Qiagen in a research note on Monday, May 18th. One analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, eight have assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, Qiagen has a consensus rating of “Hold” and a consensus price target of $42.43.

Key Qiagen News

Here are the key news stories impacting Qiagen this week:

• Positive Sentiment: Qiagen reported second-quarter adjusted EPS of $0.62, above the $0.60 consensus estimate, while revenue of $535 million exceeded expectations of $527.5 million. Revenue was broadly unchanged year over year, but the company said its growth pillars delivered 5% growth at constant exchange rates and that sales exceeded its prior outlook for a decline. QIAGEN Exceeds Q2 2026 Outlook as Pillars Deliver Solid Sales Growth; Reaffirms Full-Year Outlook
• Positive Sentiment: The company reaffirmed its full-year 2026 EPS outlook of approximately $2.43, in line with analyst expectations, while maintaining high profitability. Qiagen Earnings Conference Call
• Neutral Sentiment: Management’s second-quarter earnings call and presentation provided additional detail on the performance of Qiagen’s growth pillars and the company’s outlook, but did not materially change the full-year EPS forecast. Qiagen N.V. Q2 2026 Earnings Call Transcript
• Negative Sentiment: Third-quarter guidance was below consensus: EPS of $0.62 versus $0.63 expected and revenue of $538.3 million to $543.7 million versus $552.7 million expected. The revenue shortfall indicates analysts may need to reduce near-term estimates.
• Negative Sentiment: Although full-year EPS guidance matched consensus, full-year revenue guidance of roughly $2.1 billion was below the approximately $2.2 billion analyst estimate, tempering the impact of the quarterly beat.

About Qiagen

Qiagen NV (NYSE: QGEN) is a global provider of sample and assay technologies designed to enable molecular testing in the fields of molecular diagnostics, applied testing, academic research and pharmaceutical development. The company’s solutions span the full workflow of nucleic acid and protein analysis, offering customers standardized kits, instruments and software tools that streamline the preparation, detection and quantification of DNA, RNA and proteins.

The company’s product portfolio includes nucleic acid extraction and purification systems, polymerase chain reaction (PCR) reagents and instrumentation, digital PCR platforms, next-generation sequencing (NGS) library‐preparation kits and proteomics solutions.